Evaluating Neuroprotective Effects of Caplacizumab in Immune-Mediated Thrombotic Thrombocytopenic Purpura
Notice bibliographique
Résumé
Objective: Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a rare and life-threatening disease characterized by inhibition of the enzyme ADAMTS13 (A Disintegrin-like And Metalloprotease with Thrombospondin type 1 repeats 13). This leads to widespread formation of platelet clotting/aggregation in the small blood vessels, resulting in thrombosis and end-organ ischemia. Despite standard of care (SOC) treatment involving the use of plasma exchange and immunosuppressants, patients often suffer increased risks of cerebrovascular disease, cognitive decline, and depression. Caplacizumab has shown to be an effective treatment for iTTP by targeting binding zones on ultra-large von Willebrand factors, preventing platelets from aggregating and forming clots. This study investigates whether Caplacizumab can provide a potential neuroprotective effect in preventing/reducing brain tissue damage compared to SOC treatment. Methods: We conducted a multi-center study involving 13 iTTP patients, six of whom were refractory to SOC treatment and received Caplacizumab. Participants underwent MRI and a contrast-enhanced dynamic CT perfusion scan to assess gross pathology, blood-brain barrier (BBB) permeability, cerebral blood flow, and volume. Additionally, a comprehensive cognitive and neuropsychiatric assessment was conducted to evaluate reasoning, short-term memory, verbal memory, concentration, and depression scores. Data collection was conducted at two timepoints; baseline, 30-days post remission, and follow-up in one year. Results: BBB disruption was evident in all patients. Baseline whole brain mean permeability surface (PS) product for patients receiving Caplacizumab was 0.35 +/- 0.09 mL/min/100g, compared to SOC at 0.27 +/- 0.10 mL/min/100g. A significant reduction (p = 0.047) in the BBB integrity to 0.24 +/- 0.08 mL/min/100g was found in the Caplacizumab group at the follow-up visit. Cognitive scores presented low for all patients with verbal memory and concentration related test being one standard deviation below normative data. All patients have persistent white matter hyperintensities observed on MRI scans. No significant increases or decreases were found in follow-up cognitive scores in both groups but a significant inverse correlation with whole brain mean PS was found across all four cognitive domains, r (26) = -0.51, p = 0.007. Depression assessments revealed consistent concentration difficulties across all participants. Conclusion: Compromised BBB integrity observed in patients, regardless of remission or treatment, stresses the chronic nature of iTTP's impact on the brain. Despite patients receiving Caplacizumab having a higher whole-brain mean PS product at baseline, likely due to patients being refractory, follow-up scans show a significant reduction in whole-brain mean PS product. This highlights Caplacizumab's potential neuroprotective capabilities. However, no improvement was seen in patient cognitive scores suggesting that, while Caplacizumab may mitigate some aspects of BBB disruption, it does not reverse any cognitive impairment already developed due to iTTP. In addition, baseline cognitive scores for Caplacizumab were lower than SOC possibly as a result of higher baseline BBB permeability leading more damage of brain tissue. While Caplacizumab shows promise in reducing BBB permeability and potentially offering a neuroprotective effect, further longitudinal studies are needed to fully understand its long-term effects. These findings suggest the inclusion of Caplacizumab in standard iTTP treatment protocols with the potential to improve overall patient outcomes by mitigating some of the neurocognitive complications associated with the disease.
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction distillée sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Apprise à partir de 10 348 étiquettes directes de Codex et de 10 348 étiquettes directes de Gemma. Le mode candidate est l'union des têtes enseignantes seuillées; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont ni des étiquettes humaines ni des étiquettes directes de modèles de pointe.
Scores Codex et Gemma par catégorie
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,000 | 0,001 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,000 | 0,000 |
| Bibliométrie | 0,000 | 0,000 |
| Études des sciences et des technologies | 0,000 | 0,000 |
| Communication savante | 0,000 | 0,000 |
| Science ouverte | 0,000 | 0,000 |
| Intégrité de la recherche | 0,000 | 0,000 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,000 | 0,000 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule tête enseignante, pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».